Sugi Predict

Sugi Predict / Compounds / SCHEMBL1606644

SCHEMBL1606644

SCHEMBL1606644

CCOC(=O)C1(C=O)CCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ATM Q13315 1/20 0.38
▸ POLB P06746 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ OPRM1 P35372 7/20 0.35
▸ LMNA P02545 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ OPRD1 P41143 3/20 0.34
▸ OPRK1 P41145 3/20 0.34
▸ SLC22A1 O15245 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ ALOX15 P16050 1/20 0.33
▸ MGAM O43451 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ SI P14410 1/20 0.33
▸ MGAM2 Q2M2H8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2553541 0.96 SMN1; SMN2 (0.38) SMN1; SMN2MEN1KMT2AATMPOLB
SCHEMBL2557391 0.94 SMN1; SMN2 (0.37) SMN1; SMN2MEN1KMT2AATMPOLB
SCHEMBL508318 0.92 ALDH1A1 (0.39) SMN1; SMN2MEN1KMT2AATMPOLB
SCHEMBL19381503 0.87 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2AATMPOLB
SCHEMBL2289679 0.84 SMN1; SMN2 (0.41) SMN1; SMN2MEN1KMT2AATMPOLB
SCHEMBL11355855 0.81 SMN1; SMN2 (0.40) SMN1; SMN2MEN1KMT2AATMPOLB
SCHEMBL2290174 0.80 SMN1; SMN2 (0.38) SMN1; SMN2MEN1KMT2AATMPOLB
SCHEMBL14341367 0.79 ALDH1A1 (0.42) SMN1; SMN2KMT2AATMPOLBALDH1A1
SCHEMBL2289921 0.78 SMN1; SMN2 (0.37) SMN1; SMN2MEN1KMT2AATMPOLB
SCHEMBL8241934 0.78 POLB (0.35) SMN1; SMN2MEN1KMT2AATMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-11247992-B2 Cyclopropylamines as LSD1 inhibitors INCYTE CORPORATION (US) 2022-02-15 — — US disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 — — US disclosed
EP-3626713-B1 CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS INCYTE CORP (US) 2021-09-29 — — EP disclosed
US-20210032244-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS INCYTE CORPORATION 2021-02-04 — — US disclosed
CN-111454188-A Cyclopropylamines as L SD1inhibitors 因赛特公司 2020-07-28 — — CN disclosed
US-10717737-B2 Cyclopropylamines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-07-21 — — US disclosed
EP-3626713-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS Incyte Corporation (US) 2020-03-25 — — EP disclosed
CN-106164066-B Cyclopropylamines as LSD1inhibitors 因赛特公司 2020-01-17 — — CN disclosed
EP-3105218-B1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS INCYTE CORP (US) 2019-09-25 — — EP disclosed
EP-1703908-A4 ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO AMGEN INC (US) 2009-07-08 — — EP disclosed
US-7365075-B2 Aryl sulfonamide compounds and uses related thereto AMGEN INC. (US) 2008-04-29 — — US disclosed
US-7365075-B2 Aryl sulfonamide compounds and uses related thereto AMGEN INC. (US) 2008-04-29 — — US disclosed
US-7365075-B2 Aryl sulfonamide compounds and uses related thereto AMGEN INC. (US) 2008-04-29 — — US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 — — EP disclosed
EP-1703908-A1 ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO Amgen Inc. (US) 2006-09-27 — — EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 — — WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 — — US disclosed
US-20050277649-A1 Aryl sulfonamide compounds and uses related thereto AMGEN SF, LLC (US) 2005-12-15 — — US disclosed
WO-2005063247-A1 ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO AMGEN INC. (US) 2005-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717737-B2 Cyclopropylamines as LSD1 inhibitors KDM1B, KDM1A, KDM2A SMN1; SMN2 2689/4885MEN1 3150/4885KMT2A 25/4885
US-11247992-B2 Cyclopropylamines as LSD1 inhibitors KDM1B, KDM1A, KDM2A SMN1; SMN2 2689/4885MEN1 3150/4885KMT2A 25/4885
US-20050277649-A1 Aryl sulfonamide compounds and uses related thereto SULT2A1, ARSA, SULT1A1 SMN1; SMN2 3200/4885MEN1 4139/4885KMT2A 896/4885
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 SMN1; SMN2 4254/4885MEN1 4420/4885KMT2A 3967/4885
US-20210032244-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS KDM1B, KDM1A, KDM2A SMN1; SMN2 2689/4885MEN1 3150/4885KMT2A 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.